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Eye amputation surgery, including evisceration and enu-
cleation, is performed in patients with progressive phthisis 
bulbi, severe microphthalmia, endophthalmitis and intra-
ocular neoplasm, or in patients who suffer from pain in a 
blind eye resulting from trauma, retinal detachment, or end-
stage glaucoma [1]. Many patients who undergo these pro-
cedures may suffer from severe postoperative orbital pain, 
nausea, and vomiting that may delay a prompt recovery and 
their return to work. To minimize postoperative pain, di-
verse administration of analgesics, orally, intravenously, or 
intraorbitally, and intraoperative retrobulbar blockage have 
been used [2,3]. Fentanyl is a strong opioid analgesic usu-
ally administered intravenously by patient-controlled anal-
gesia (IV-PCA) [4-6]. Postoperative nausea and vomiting 
(PONV) are the most distressing side effects of fentanyl, 
Purpose: To investigate the analgesic effect and incidence of postoperative nausea and vomiting (PONV) 
between the opioid fentanyl and the non-steroidal anti-inflammatory drug ketorolac in patients who underwent 
eye amputation surgery. 
Methods: Retrospective observational case series. Eighty-two patients underwent evisceration or enucleation 
surgery by one surgeon over a 2-year period. Fentanyl by intravenous patient-controlled analgesia (IV-PCA) 
at 20 µg/kg with 12 mg/kg ondansetron or intravenous ketorolac at 2 mg/kg/day was administered to patients 
at postoperative days 0, 1, and 2. The pain score was measured using an 11-point visual analog scale (VAS). 
The incidence of severe nausea requiring anti-emetics and the incidence of vomiting were reviewed.
Results: The mean postoperative VAS in the fentanyl group was significantly lower than that in the ketorolac 
group on the day of operation for both types of surgery (p = 0.001 and p = 0.004, respectively). At 
postoperative days 1 and 2, the mean VAS was not different between the two groups for either surgical type 
(p > 0.05 for both days). The mean VAS was significantly higher in eviscerated patients than in enucleated 
patients at postoperative days 0 and 1 in the fentanyl group (p = 0.023 and p = 0.016, respectively). However, 
this was not observed in the ketorolac group. The incidence of PONV was higher in the fentanyl group than 
in the ketorolac group, although this was not statistically significant for either surgical type (p > 0.05 for both 
groups).
Conclusions: Fentanyl was more effective as an analgesic than was ketorolac on the day of operation for both 
surgical types. There was no difference between the two analgesics on postoperative day 1. The analgesic 
effect of fentanyl in enucleated patients was significantly higher than in eviscerated patients at postoperative 
days 0 and 1. The use of fentanyl by IV-PCA was associated with greater PONV despite co-administration 
with anti-emetics, although this finding was not significant.
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although anti-emetics are mixed with the PCA solutions [7-
10]. Often, IV-PCA of fentanyl cannot be continued due to 
severe refractory PONV. This is especially true in patients 
who undergo eye amputation surgery. The use of fentanyl 
is sometimes problematic due to its emetic effect after eye 
amputation surgery in spite of its satisfactory pain-relieving 
effects. Though non-steroidal anti-inflammatory drugs have 
weaker analgesic effect than opioids, they can be used for 
safely controlling postoperative pain without physical or 
mental dependency, serious withdrawal, or PONV symp-
toms.  
For these reasons, we investigated the efficacy and safety 
of IV-PCA fentanyl and IV ketorolac. The goal of our study 
was to determine which drug provided the strongest anal-
gesic effect with the fewest side effects. We also compared 
the results between patients who underwent enucleation to 
those who underwent evisceration. To our knowledge, there 
has been no study investigating and comparing the post-
operative pain-relieving efficacy and incidence of PONV 
in patients that were administered fentanyl in comparison 
with non-steroidal anti-inflammatory drugs (NSAIDs) after 
eyeball removal surgery. 
Materials and Methods
A retrospective chart review of patients who underwent 
eye amputation surgery, including evisceration or enucle-
ation, performed by one surgeon (JSY) at Severance Hos-
pital, Yonsei University College of Medicine, Seoul, Korea 
from January 2010 until December 2011 was performed. 
Informed consent was obtained from all patients in com-
pliance with the World Medical Association Declaration 
of Helsinki. The pain score measurement used an 11-point 
visual analog scale (VAS; 0 = no pain, 10 = worst and intol-
erable pain) [11]. The incidence of severe nausea requiring 
anti-emetics, vomiting, or interrupting infusion of IV-PCA 
of fentanyl due to severe emesis was reviewed. A self-re-
port of pain score was only achieved in patients over the 
age of 15 due to reliability, and patients under 15 years of 
age were excluded from this study. The survey of self-re-
ported pain scores was conducted each evening from post-
operative day 0 to day 2 after surgery. Pain was measured 
in the evening because that was when the last of the three 
daily doses of ketorolac was administered.
Postoperative pain was controlled by either IV-PCA 
fentanyl or IV ketorolac (Keromin; Hana Pharmaceuticals, 
Seoul, Korea). The IV-PCA (Automed 3400; Acemedical, 
Seoul, Korea) consisted of fentanyl dosed at 20 μg/kg body 
weight and ondansetron (Onseran; Yuhan Products, Seoul, 
Korea) dosed at 12 mg in normal saline at a total volume of 
100 mL. It was administered at a basal rate of 2 mL/h, with 
a bolus dose of 0.5 mL and a lockout time of 15 minute. 
Due to the emetic side effects of fentanyl, anti-emetics were 
routinely mixed with fentanyl during IV-PCA. Ketorolac 
tromethamine was administered intravenously at three dif-
ferent times at 2 mg/kg body weight per day. The selection 
of analgesics was dependent upon the patient’s decision and 
economic status. Informed consent was obtained for the use 
of IV-PCA fentanyl or IV ketorolac. 
The evisceration or enucleation was performed under 
general anesthesia using standard techniques with the 
placement of hydroxyapatite (HA) orbital implants. During 
evisceration, a corneal button was removed after a 360° 
peritomy, and the intraocular contents were curetted with a 
360° posterior sclerotomy performed to allow the placement 
of a larger HA implant and to facilitate vascularization [12]. 
During enucleation, the superior and inferior oblique mus-
cles were cut and not reattached. The size of the HA im-
plant was determined using sizing spheres, which allowed 
for sufficiently deep placement of the implant. After mak-
ing three small holes in the HA implant using a 19-gauge 
needle, the anterior surface was wrapped with prepared au-
togenous sclera with the optic nerve stump facing forward 
or with a Neuro-Patch (polyester-urethane; Aesculap Inc., 
Tuttlingen, Germany) and fixed with 5-0 Vicryl sutures 
posteriorly [12,13]. Four windows (4 × 2 mm) were made at 
the attachment sites of the rectus muscles, and the implant 
was inserted into the orbit. Four rectus muscles were then 
brought into contact with the implant by passing a dou-
ble-armed 5-0 Vicryl suture through the anterior lip of the 
window and tying the muscles to the opening. The last step 
was careful closure of the anterior and posterior Tenon’s 
capsules and conjunctiva as separate layers.
Statistical analysis was performed with SPSS ver. 18.0 
(SPSS Inc., Chicago, IL, USA) using independent t-tests, 
paired t-tests, and Pearson’s chi-square tests to compare 
the mean VAS and incidence of PONV between the two 
analgesic groups. Differences between evisceration and 
enucleation were also compared. A value of p < 0.05 was 
considered significant.
Results
A total of 82 eyes from 82 patients (42 patients in the 
fentanyl group and 40 patients in the ketorolac group) were 
eligible for the study. Table 1 shows the demographic find-
ings in patients given IV-PCA fentanyl or IV ketorolac after 
evisceration or enucleation. 
In eviscerated patients (n = 46), the mean VAS at day 0 
of surgery was significantly higher in patients using ke-
torolac (mean, 6.8; standard deviation [SD], 2.4) than in 
patients using fentanyl (mean, 3.6; SD, 1.5; p < 0.001; two 
sample t-test) (Table 2, Fig. 1A and 1B). However, the mean 
VAS values at days 1 and 2 were not significantly different 
between the two groups (p = 0.123 and 0.645, respectively). 
In addition, the pain score significantly decreased during 
the postoperative period in both analgesic groups (paired 
t-test at days 0 and 2, p = 0.004 in fentanyl group, p = 0.001 
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in ketorolac group). 
Similarly, in patients who underwent enucleation surgery 
(n = 36), the mean VAS in the fentanyl group was sig-
nificantly lower (mean, 2.5; SD, 1.3) than in the ketorolac 
group (mean, 5.7; SD, 3.2) at day 0 of surgery (p = 0.004, 
two sample t-test) (Table 2, Fig. 1A and 1B). However, the 
mean VAS values at days 1 and 2 were not significantly 
different between the two groups (p = 0.106 and p = 0.952, 
respectively). In addition, the pain score significantly de-
creased during the postoperative period in both analgesic 
groups (paired t-test at days 0 and 2, p = 0.007 in fentanyl 
group, p = 0.004 in ketorolac group).
In a comparison of postoperative pain scores between 
enucleated patients and eviscerated patients in the fentanyl 
group, enucleated patients had significantly lower postoper-
ative pain than eviscerated patients at day 0 and day 1 (two 
sample t-test, p = 0.023 and p = 0.016, respectively) (Table 
3, Fig. 1A and 1C). However, the mean pain scores were 
not different at day 2 (p = 0.550). The pain scores were 
not significantly different between eviscerated patients and 
enucleated patients in the ketorolac group through all post-
operative days (two sample t-test; p = 0.225 at day 0, p = 
Table 1. Preoperative demographics for the evisceration and enucleation groups
Evisceration Enucleation
Fentanyl Ketorolac Fentanyl Ketorolac
No. of eyes                   19                  27                   23                   13
Mean (±SD) age (yr) 47.2 ± 13.4 51.9 ± 19.1 48.7 ± 16.2 52.3 ± 19.9
Age range (yr) 29-71 17-85 16-73 19-84
Laterality (OD / OS)  8 / 11   8 / 19 12 / 11 7 / 6
Male / female                 13 / 6 14 / 13   9 / 14 5 / 8
Diagnosis 
  Trauma              12              15                     3                     2
  Tumor                 0               0                   16                     9
  Glaucoma                3               4                     0                     1
  Inflammation/infection                3                5                     2                     0
  Retinal detachment                0                2                     1                     1
  Others                1                1                     1                     0
Table 2. Postoperative pain scores for the evisceration and enucleation groups (mean ± SD)
POD 0 day POD 1 day POD 2 day  p-value†
Evisceration Fentanyl 3.59 ± 1.51 2.44 ± 1.36 1.90 ± 1.87 0.004
 Ketorolac 6.77 ± 2.42 3.20 ± 1.90 2.23 ± 2.35 0.001
p-value*     0.001     0.123    0.645
Enucleation Fentanyl 2.47 ± 1.32 1.56 ± 0.89 1.59 ± 1.11 0.007
 Ketorolac 5.65 ± 3.21 2.65 ± 2.17 1.62 ± 1.66 0.004
p-value*     0.004     0.106     0.952
POD = postoperative day.
*Independent samples t-test; †Paired t -test (POD 0 and 2).
Table 3. Postoperative pain scores for the fentanyl and ketorolac groups (mean ± SD)
POD 0 day POD 1 day POD 2 day  p-value†
Fentanyl Evisceration 3.59 ± 1.51 2.44 ± 1.36 1.90 ± 1.87 0.004
Enucleation 2.47 ± 1.32 1.56 ± 0.89 1.59 ± 1.15 0.007
p-value*     0.023     0.016     0.550
Ketorolac Evisceration 6.77 ± 2.42 3.20 ± 1.90 2.23 ± 2.35 0.001
Enucleation 5.65 ± 3.21 2.65 ± 2.17 1.62 ± 1.66 0.004
p-value*     0.225    0.419     0.429
POD = postoperative day.
*Independent samples t-test; †Paired t-test (POD 0 and 2). 
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0.419 at day 1, and p = 0.429 at day 2).
The incidence of nausea requiring anti-emetics was high-
er in the fentanyl group (n = 10, 23.8%) than in the ketoro-
lac group (n = 6, 15.0%), although these numbers are not 
significantly different (p = 0.361, Pearson’s chi-square test) 
(Fig. 2). The incidence of vomiting was also higher in the 
fentanyl group (n = 9, 21.4%) than in the ketorolac group (n 
= 6, 15.0%), although there was not a significant difference 
(p = 0.856, Pearson’s chi-square test) (Fig. 2). In each surgi-
cal type, the number of patients with severe nausea requir-
ing anti-emetics was higher in the IV-PCA with fentanyl 
group (n = 5, 11.9%, eviscerated; n = 5, 11.9%, enucleated) 
than in the ketorolac group (n = 4, 10.0%; n = 2, 5.0%) (p = 
0.528 and p = 0.841, respectively). Similarly, 9.5% (4 / 42) 
of patients in the IV-PCA fentanyl group who underwent 
evisceration suffered from vomiting compared to 10.0% (4 
/ 40) of patients in the ketorolac group; on the other hand, 
11.9% (5 / 42) enucleation patients in the IV-PCA fentanyl 
group experienced vomiting compared to 5.0% (2 / 40) in 
the ketorolac group (p = 0.528 and p = 0.644, respectively). 
Of the 42 patients in the fentanyl group, temporal discon-
tinuation of IV-PCA fentanyl was necessary in 11 patients 
(26.2%) due to severe PONV.
Discussion
Postoperative pain, nausea, and vomiting are the most 
common and distressing complications after enucleation or 
evisceration surgery. Many studies on the management of 
postoperative morbidity have been investigated [4-8]. Op-
tic nerve-related surgery such as eye amputation is related 
to severe orbital pain and to the oculo-emetic reflex. Prior 
studies indicate that approximately 50% to 75% of enucle-
ated patients under general anesthesia experience nausea 
and vomiting on the day of surgery [2]. Therefore, immedi-
ate and proper control of pain, nausea, and vomiting is im-
portant for prompt recovery and psychological adaptation 
to loss of the eye. 
Currently, intravenous analgesics have been widely ad-
ministered for pain control. These pain relievers have some 
advantages over procedures such as indwelling intraorbital 
cannula or retrobulbar anesthetics in that they are simple 
Pa
in 
sc
ale
POD 0 POD 1 POD 2
p = 0.001
p = 0.004
10
8
6
4
2
0
Fentanyl, evisceration 
Fentanyl , enucleation
Ketorolac, evisceration
Ketorolac, enucleation
10
8
6
4
2
0
Pa
in 
sc
ale
POD 0 POD 1 POD 2
p = 0.023
p = 0.016
Evisceration, fentanyl
Evisceration, ketorolac
Enucleation, fentanyl
Enucleation, ketorolac
Pa
in 
sc
ale
POD 0 POD 1 POD 2
Fentanyl, evisceration 
Fentanyl, enucleation
Ketorolac, evisceration
Ketorolac, enucleation
10
8
6
4
2
0
A B
C
Fig. 1. (A) Total postoperative pain analogue scores recorded by 
patients who received analgesics after evisceration or enucleation 
surgery. (B) Postoperative pain analogue scores compared by 
analgesic after eye amputation surgery. Circles (fentanyl group)
and triangles (ketorolac group). (C) Postoperative pain analogue 
scores compared by surgical type. Circles (evisceration group) 
and triangles (enucleation group). POD = postoperative day.
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and safe for patients. They also exhibit good pain-relieving 
effects. Opioids have strong analgesic effects, so they are 
generally used as part of routine postoperative pain man-
agement [4,5]. The benefit of IV-PCA, which offers greater 
patient satisfaction compared to intermittent intramuscular 
injection of opioids, has been studied [14,15]. Analgesics 
such as opioids are well known causes of PONV, which is 
the most common side effect. Sex (females have greater 
potential), smoking status, history of PONV and/or motion 
sickness, duration of surgery >1 hour, and the use of post-
operative opioids were determined to be the strongest pre-
dictors of PONV [16,17]. To reduce PONV, an opioid-free 
pain management regimen can be effective [7,8]. The use of 
supplemental pain relievers such as cyclooxygenase-2-se-
lective NSAIDs could reduce opioid use and the incidence 
of PONV [18,19]. Ketorolac tromethamine is a potent 
non-narcotic analgesic NSAID agent for treating moderate 
to severe pain and can be successfully used as an alterna-
tive to opiates. With its superior analgesic activity, reduced 
emetic effect, and non-sedative properties, it is safe and 
cost effective compared with opioids ($7.6 vs. $131.5 with 
total dosage, respectively). Thus, ketorolac is recommended 
as an appropriate alternative pain-control medication. We 
studied whether fentanyl-based PCA or ketorolac is a more 
effective management strategy for reducing pain, nausea, 
and vomiting symptoms after eyeball removal surgery. 
We observed significant differences in the mean post-
operative pain scores on the day of surgery between the 
fentanyl and ketorolac groups undergoing evisceration or 
enucleation surgery. There was significantly less pain noted 
by the fentanyl group vs. the ketorolac group (p = 0.001 
and p = 0.004, respectively). This indicates that the onset 
of analgesia with fentanyl is immediate and very effective 
in patients with acute, severe pain. After the day of surgery, 
ketorolac also showed good analgesic effects similar to 
those of fentanyl. There were no differences in the mean 
pain scores between groups of patients undergoing either 
evisceration or enucleation (p > 0.05, both groups).
In patients in the fentanyl group, the mean VAS of evis-
cerated patients was significantly higher than that of enu-
cleated patients at days 0 and 1 (p = 0.023 and p =0.016, re-
spectively). Fentanyl provided a more significant analgesic 
effect in patients after enucleation than after evisceration. 
Also, in the ketorolac group, eviscerated patients experi-
enced more pain than enucleated patients, but this differ-
ence was not significant. This may be because of the large 
standard deviation of the mean VAS in the ketorolac group 
caused by variability of assessed pain score after intrave-
nous injection. Similar to a previous report [20], patients 
undergoing evisceration may experience more pain than 
those undergoing enucleation. This is thought to be due to 
exposure of ciliary nerves in evisceration but not in enucle-
ation [3].
As mentioned above, female sex has been shown to be 
a predictive factor of PONV. There was a significant sex 
difference in PONV in the fentanyl group but not in the ke-
torolac group. In the fentanyl group (n = 42), the incidence 
of severe nausea in females (n = 8, 19.0%) was greater 
than in males (n = 2, 4.8%), and the female patients (n = 7, 
16.7%) tended to have more frequent vomiting events than 
male patients (n = 2, 4.8%). These scores are significantly 
different (p = 0.011 and p = 0.024, respectively). 
Because of the emetic effect of fentanyl, prophylactic 
use of anti-emetics such as ondansetron can be beneficial. 
Ondansetron binds to 5-HT3 receptors both in the central 
chemoreceptor trigger zone and the gastrointestinal tract 
to inhibit emetic symptoms and is widely used to prevent 
PONV [7,8,10]. This treatment was also used in our study. 
The recommended dose for prophylaxis is 4 to 8 mg IV 
in adults [21]. Therefore, we mixed 12 mg of ondansetron 
into the PCA. In another study, despite the addition of on-
dansetron to the PCA, the incidence of PONV in patients 
with fentanyl with PCA was reported to be as high as 58% 
[19]. In our study, ten of 42 patients receiving IV-PCA with 
fentanyl (23.8%) and six patients of the 40 patients receiv-
ing ketorolac (15.0%) had PONV symptoms requiring an-
ti-emetics. The incidence of PONV with patients receiving 
fentanyl-based PCA was higher than those administered 
ketorolac in spite of adding anti-emetics to the PCA solu-
tion. However, this difference between the two groups was 
not significant. Prophylactic anti-emetic addition to the 
PCA made it difficult to compare the incidence of PONV 
between IV-PCA fentanyl and ketorolac alone. This was a 
limitation in our study. Overall, the PONV frequency in our 
study was much lower than that reported in prior studies, 
which reported 50% to 75% incidence of PONV after enu-
cleation under general anesthesia [2]. This may be because 
we only recorded the incidence of severe nausea and vomit-
ing requiring anti-emetics and excluded the cases of mild to 
moderate PONV. We could consider using a more objective 
measurement of PONV, such as a postoperative verbal nu-
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merical rating scale (VNRS), after eyeball removal surgery. 
To assess the severity of pain or nausea and vomiting 
symptoms, patients were asked to assess the degree of 
severity. Therefore, one limitation in this study was de-
pendent upon the patient recall during the study period. 
Patients were asked to estimate the level of pain only once 
a day in the evening. This does not reflect changes or varia-
tion of pain throughout the day. 
Meanwhile, more effective options to reduce both post-
operative pain and PONV after eye amputation surgery 
should be considered. As an alternative to opioids, μ-opioid 
receptor antagonists such as naloxone can also be consid-
ered to reduce emetic effects along with relieving pain [7]. 
A preliminary study comparing naloxone with placebo 
treatment demonstrated its effectiveness in reducing the 
incidence of PONV [22]. An additional method is syner-
gic use of an NSAID-opioid combination. Prior reports 
demonstrated that the NSAID ketorolac combined with 
lower doses of the opioid fentanyl was associated with the 
same analgesic efficacy but reduced nausea and vomiting 
after thyroid surgery. This demonstrates the excellent opi-
oid-sparing effect of ketorolac [19].
In conclusion, fentanyl was a significantly stronger pain 
reliever than ketorolac for the immediate postoperative pe-
riod. However, the effect of pain reduction was similar to 
that of ketorolac after postoperative day 1 for eye amputa-
tion surgery. As patients receiving fentanyl-based PCA are 
more likely to experience PONV, more active administra-
tion of anti-emetics, if needed, should be considered.
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